Carboxylated Particles for Inflammatory Immune Response Amelioration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases and disorders, such as autoimmune diseases and infections, often rely on long-term immunosuppressive drugs with toxic side effects or antigen-specific tolerance methods that are costly, complex, and limited by the need for tissue-matched cells and specific antigen identification.
Innovation Solution
Administration of carboxylated particles, such as polystyrene, diamond, or PLGA particles, without peptide coupling, which effectively ameliorate inflammatory immune responses by inducing immune tolerance and reducing the severity of inflammatory conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad acting immunosuppressive drugs are used for long-term immunosuppression, then immune response is suppressed, but toxic side effects increase
Solution Approach 1:
The patent uses carboxylated particles as an intermediary carrier to deliver antigens to the immune system. These particles act as a mediator between the antigen and immune cells, enabling antigen-specific tolerance induction without requiring broad immunosuppressive drugs. The particles facilitate controlled antigen presentation that induces regulatory T cells, achieving immunosuppression targeted at specific antigens rather than system-wide suppression.
Solution Approach 2:
The patent modifies particle parameters (carboxylation, size, surface properties) to optimize immune cell uptake and antigen presentation. By changing the physical and chemical parameters of the particle carrier, the invention achieves enhanced delivery of antigens to dendritic cells and other immune cells, enabling effective antigen-specific tolerance with lower doses and reduced toxicity compared to broad immunosuppressants.
2Reliability
If antigen-specific tolerance methods are used, then immune response to specific antigens is reduced, but treatment complexity and cost increase
Solution Approach 1:
The patent extracts the essential functional components needed for antigen-specific tolerance (antigen delivery and presentation) and isolates them from the complexity of whole cell coupling methods. By using simplified carboxylated particles instead of complex cell-based systems, the invention maintains antigen-specific tolerance effectiveness while dramatically reducing treatment complexity, eliminating the need for cell isolation, culturing, and coupling procedures.
Solution Approach 2:
The patent creates simplified particle-based copies or models of natural antigen presentation systems. Instead of using actual antigen-presenting cells with all their complexity, the invention develops synthetic carboxylated particles that replicate the essential function of antigen delivery and presentation, achieving the same immunological effect with a much simpler, more scalable system.
3Reliability
If cell coupling methods are used for antigen-specific tolerance, then antigen delivery is achieved, but source cell supply and tissue matching requirements limit accessibility
Solution Approach 1:
The patent replaces expensive, difficult-to-obtain living cells with inexpensive, easily manufactured synthetic particles. The carboxylated particles can be produced in large quantities through simple chemical modification of commercial particles, eliminating the need for costly cell isolation, expansion, and quality control procedures. These particles are disposable and do not require tissue matching, making the treatment universally accessible.
Solution Approach 2:
The patent creates a universal particle platform that can deliver any antigen by simply changing the antigen coating, without requiring different cell types or tissue matches. The carboxylated particles serve multiple functions: they can be produced from any source, modified to carry different antigens, and administered to any patient regardless of tissue compatibility, making the system universally applicable to various autoimmune diseases and transplant scenarios.
Data Source
AI summary
The current invention involves the surprising finding that when carboxylated particles, such as carboxylated poly-styrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles.